Drug Profile
OPNT 005
Alternative Names: Adjuvanted heroin analogue vaccine - Opiant; diamorphine analogue vaccine - Opiant Pharmaceuticals; Heroin vaccine - Opiant; OPNT-005; OPNT005 Heroin Vaccine: hapten + liposome adjuvantLatest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator National Institute on Drug Abuse; Walter Reed Army Institute of Research
- Developer Opiant Pharmaceuticals; Walter Reed Army Institute of Research
- Class Drug withdrawal therapies; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Heroin-related disorders
Most Recent Events
- 02 Mar 2023 Opiant Pharmaceuticals has been acquired by Indivior
- 27 Oct 2021 Phase-I clinical trials in Heroin-related disorders in USA (unspecified route)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Heroin-related-disorders in USA